Predicting Overall Survival in Patients With Metastatic Melanoma on Antiangiogenic Therapy and RECIST Stable Disease on Initial Posttherapy Images Using CT Texture Analysis | AJR
Radium-223 in combination with enzalutamide in metastatic castration-resistant prostate cancer: a multi-centre, phase II open-label study - Raymond S. McDermott, John Greene, John McCaffrey, Imelda Parker, Sylva Helanova, Anne-Marie Baird, Ausra ...
Exploring the relationship between Overall Survival (OS), Progression Free Survival (PFS) and Objective Response Rate (ORR) in patients with advanced melanoma - ScienceDirect
PPT - Overall Survival and Progression-Free Survival PowerPoint Presentation - ID:4064400
Measures of Cancer Survival
Survival Analysis
A Primer on RECIST 1.1 for Oncologic Imaging in Clinical Drug Trials | Radiology: Imaging Cancer
Improved overall survival for Hodgkin lymphoma with brentuximab vedotin - Mayo Clinic
Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast. - ppt download
Kaplan-Meier curve for overall survival (MOS, mean overall survival;... | Download Scientific Diagram
Definition of progression free survival and overall survival for the... | Download Scientific Diagram
What does "Overall Survival" and "Progression Free Survival" mean? - YouTube
Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive
Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper
View Image
Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects | Nature Communications
Kaplan-Meier survival analysis
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
Cancers | Free Full-Text | Navigating Choices: Determinants and Outcomes of Surgery Refusal in Thyroid Cancer Patients Using SEER Data
Event-free survival > Overall survival? - data analysis - Datamethods Discussion Forum
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
Gini's mean difference and the long-term prognostic value of nodal quanta classes after pre-operative chemotherapy in advanced breast cancer | Scientific Reports
Disease-free survival as a measure of overall survival in resected pancreatic endocrine neoplasms in: Endocrine-Related Cancer Volume 27 Issue 5 (2020)
Survival Analysis Using the Covid-death Mean-imputation (CoDMI) Algorithm: A First Clinical Application in Radiation Oncology | In Vivo
Restricted Mean Survival Time: An Obligatory End Point for Time-to-Event Analysis in Cancer Trials? | Journal of Clinical Oncology
